Jiangsu Nhwa Pharmaceutical Co Ltd (002262.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100000CG8

Price
21.59 CNY
Market cap
21.93 bn CNY
P/E (2025)
20.74
P/S (2025)
3.71
Dividend yield
1.85 %
Net margin
17.89 %
Return on equity (ROE)
13.12 %
Return on assets (ROA)
11.46 %

Jiangsu Nhwa Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue5.70 bn CNY5.91 bn CNY
Gross profit4.15 bn CNY4.26 bn CNY
Operating income1.34 bn CNY1.16 bn CNY
EBIT1.21 bn CNY1.18 bn CNY
Net income1.14 bn CNY1.06 bn CNY
Diluted EPS – continuing operations1.13 CNY1.04 CNY

Full history since 2005, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Jiangsu Nhwa Pharmaceutical Co Ltd

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.